Pfizer may also consider retaining the business, one of the largest over the counter products businesses in the world, operating in 90 countries. It markets two of the ten top-selling consumer ...

The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.

Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...

Pfizer Inc. (NYSE: PFE) hit its peak during the COVID-19 pandemic when its vaccines developed with BioNTech SE (NASDAQ: BNTX) ...

Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding ...

Pfizer has so far signed up less than a quarter of the countries targeted under a plan to make its medicines available to the ...

Pfizer Inc. plans to sell 540 million worth of shares in Haleon Plc, as it pares back its holding in the UK consumer health ...

Pfizer has sold a stake in British consumer healthcare group Haleon worth about $3.26 billion, cutting its shareholding in ...

Some blame Pfizer. The firm is struggling to replace ... “We knew we could make a consumer product. Our major generational advantage was based on the simplicity of the device,” he says.

Lower interest rates make these stand-out dividend payers must-see investments for those who want passive income.

The sale is part of a broader scheme by GSK and Pfizer to reduce their holdings in the consumer health venture ... offloaded its ChapStick line of products to Suave Brands Company for $430 million.

Pfizer will receive around 2.66 billion pounds ... pharmaceutical company sold 640 million ordinary shares in British consumer-healthcare business Haleon at 380 pence a share.